Low dose β blockade in acute stroke (“BEST” trial): An evaluation

British Medical Journal (Clinical research ed.)

Volumn 296, Issue 6624, 1988, Pages 737-741

  Barer, D H ^a   Cruickshank, J M ^b   Ebrahim, S B ^a   Mitchell, J R A ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b Pharmaceuticals Division ^*  (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

DRUG THERAPY; FATALITY; MAJOR CLINICAL STUDY; NORMAL HUMAN; PRIORITY JOURNAL; STROKE;

ACTIVITIES OF DAILY LIVING; AGED; ATENOLOL; BRAIN; CEREBROVASCULAR DISORDERS; CLINICAL TRIALS; COMPARATIVE STUDY; FEMALE; HEMODYNAMICS; HUMAN; LENGTH OF STAY; MALE; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPRANOLOL; RANDOM ALLOCATION; RESEARCH DESIGN; SUPPORT, NON-U.S. GOV'T;

EID: 0023839226     PISSN: 02670623     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.296.6624.737     Document Type: Article

References (14)

1. Harrison M. J. G. Russell RWR. Medical treatment. In: Harrison M. J. G. Dyken M. L. eds. Cerebral vascular disease. London: Butterworths, 1983:254-83.
2. Spence J. D. Donner A. Problems in design of stroke treatment trials. Stroke 1982;13:94-9.
3. Pocock S. J. Statistical methods in the design and analysis of long-term clinical trials. In: Tognoni G. Garattini S. eds. Drug treatment and prevention of cerebrovascular disorders. Amsterdam: Elsevier/North Holland, 1979:327-42.
4. Dego R. A. Measuring functional outcomes in therapeutic trials for chronic diseases. Controlled Clin Trials 1984;5:223-40.
5. Steiner T. J. Clifford-Rose F. Towards a model stroke trial: the single-centre naftidrofuryl study. Neuroepidemiology 1986;5:121-47.
6. Bayer A. J. Pathy MS J. Newcombe R. Double-blind randomised trial of intravenous glycerol in acute stroke. Lancet 1987;i:405-7.
7. Little J. R. Latchaw J. P. Slugg R. M. Lesser R. P. Stowe N. T. Treatment of acute focal cerebral ischaemia with propranolol. Stroke 1982;13:302-7.
8. Meyer J. S. Okamoto S. Shimazu K. et al. Cerebral metabolic changes during treatment of subacute cerebral infarction by alpha and beta adrenergic blockade with phenoxybenzamine and propranolol. Stroke 1974;5:180-95.
9. Neil-Dwyer G, Walter P. Cruickshank J. M. Doshi B. O'Gorman P. Effect of propranolol and phentolamine on myocardial necrosis after subarachnoid haemorrhage. Br. Med. J 1978;ii:990-2.
10. Walter P. Neil-Dwyer G, Cruickshank J. M. Beneficial effects of adrenergic blockade in patients with subarachnoid haemorrhage. Br. Med. J 1982;284:1661-4.
11. Neil-Dwyer G, Bartlett J. McAinsh J. Cruickshank J. M. Beta adrenoceptor blockers and the blood-brain barrier. Br J Clin Pharmacol 1981;11:549-53.
12. Aho K. Harmsen P. Hatano S. Marquardsen J. Smirnov V. E. Strasser T. Cerebrovascular disease in the community: results of a WHO collaborative study. Bull WHO 1980;58:113-30.
13. Barer D. H. Ebrahim S. B. Mitchell JRA. The pragmatic approach to stroke trial design: stroke register, pilot trial, assessment of neurological then functional outcome. Neuroepidemiology 1988;7:1-12.
14. Ebrahim S. Nouri, Barer D. Measuring disability after stroke. J Epidemiol Community Health 1985;39:86-9.